Literature DB >> 15684379

Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Chandrashekhar Korgaonkar1, Jussara Hagen, Van Tompkins, April A Frazier, Chantal Allamargot, Frederick W Quelle, Dawn E Quelle.   

Abstract

The ARF tumor suppressor is a nucleolar protein that activates p53-dependent checkpoints by binding Mdm2, a p53 antagonist. Despite persuasive evidence that ARF can bind and inactivate Mdm2 in the nucleoplasm, the prevailing view is that ARF exerts its growth-inhibitory activities from within the nucleolus. We suggest ARF primarily functions outside the nucleolus and provide evidence that it is sequestered and held inactive in that compartment by a nucleolar phosphoprotein, nucleophosmin (NPM). Most cellular ARF is bound to NPM regardless of whether cells are proliferating or growth arrested, indicating that ARF-NPM association does not correlate with growth suppression. Notably, ARF binds NPM through the same domains that mediate nucleolar localization and Mdm2 binding, suggesting that NPM could control ARF localization and compete with Mdm2 for ARF association. Indeed, NPM knockdown markedly enhanced ARF-Mdm2 association and diminished ARF nucleolar localization. Those events correlated with greater ARF-mediated growth suppression and p53 activation. Conversely, NPM overexpression antagonized ARF function while increasing its nucleolar localization. These data suggest that NPM inhibits ARF's p53-dependent activity by targeting it to nucleoli and impairing ARF-Mdm2 association.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684379      PMCID: PMC548001          DOI: 10.1128/MCB.25.4.1258-1271.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  86 in total

Review 1.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

2.  Protein B23 is an important human factor for the nucleolar localization of the human immunodeficiency virus protein Tat.

Authors:  Y P Li
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa.

Authors:  Y Nozawa; N Van Belzen; A C Van der Made; W N Dinjens; F T Bosman
Journal:  J Pathol       Date:  1996-01       Impact factor: 7.996

4.  C23 interacts with B23, a putative nucleolar-localization-signal-binding protein.

Authors:  Y P Li; R K Busch; B C Valdez; H Busch
Journal:  Eur J Biochem       Date:  1996-04-01

5.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.

Authors:  R Montes de Oca Luna; D S Wagner; G Lozano
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

6.  A novel p16INK4A transcript.

Authors:  L Mao; A Merlo; G Bedi; G I Shapiro; C D Edwards; B J Rollins; D Sidransky
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

7.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

8.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.

Authors:  N Yoneda-Kato; A T Look; M N Kirstein; M B Valentine; S C Raimondi; K J Cohen; A J Carroll; S W Morris
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

9.  Complex structure and regulation of the P16 (MTS1) locus.

Authors:  S Stone; P Jiang; P Dayananth; S V Tavtigian; H Katcher; D Parry; G Peters; A Kamb
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

10.  A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies.

Authors:  D Duro; O Bernard; V Della Valle; R Berger; C J Larsen
Journal:  Oncogene       Date:  1995-07-06       Impact factor: 9.867

View more
  121 in total

1.  RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis.

Authors:  Anthony J Saporita; Hsiang-Chun Chang; Crystal L Winkeler; Anthony J Apicelli; Raleigh D Kladney; Jianbo Wang; R Reid Townsend; Loren S Michel; Jason D Weber
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  Proteasome inhibitors suppress expression of NPM and ARF proteins.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 3.  Nucleophosmin and human cancer.

Authors:  Mi Jung Lim; Xin Wei Wang
Journal:  Cancer Detect Prev       Date:  2006-11-17

4.  New centromeric component CENP-W is an RNA-associated nuclear matrix protein that interacts with nucleophosmin/B23 protein.

Authors:  Younghwa Chun; Byoungwoo Park; Wansoo Koh; Sunhee Lee; Yeongmi Cheon; Raehyung Kim; Lihua Che; Soojin Lee
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

5.  Spotting new DNA damage-responsive chromatin-binding proteins.

Authors:  Benjamin N Wardleworth; Jessica A Downs
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

6.  Compartmentation of the nucleolar processing proteins in the granular component is a CK2-driven process.

Authors:  Emilie Louvet; Henriette Roberte Junéra; Isabelle Berthuy; Danièle Hernandez-Verdun
Journal:  Mol Biol Cell       Date:  2006-03-15       Impact factor: 4.138

Review 7.  Nucleolar targeting: the hub of the matter.

Authors:  Edward Emmott; Julian A Hiscox
Journal:  EMBO Rep       Date:  2009-02-20       Impact factor: 8.807

8.  Study on the spatial architecture of p53, MDM2, and p14ARF containing complexes.

Authors:  Andrej Savchenko; Mariya Yurchenko; Boris Snopok; Elena Kashuba
Journal:  Mol Biotechnol       Date:  2008-11-07       Impact factor: 2.695

Review 9.  Insights into the regulation of neuronal viability by nucleophosmin/B23.

Authors:  Jason A Pfister; Santosh R D'Mello
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-22

10.  A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.

Authors:  Galina A Gusarova; I-Ching Wang; Michael L Major; Vladimir V Kalinichenko; Timothy Ackerson; Vladimir Petrovic; Robert H Costa
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.